The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis
Open accessAbstract
BACKGROUND: The 18-month efficacy of a single course of rituximab as compared with conventional immunosuppression with cyclophosphamide followed by azathioprine in patients with severe (organ-threatening) antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is unknown. METHODS: In a multicenter, randomized, double-blind, double-dummy, noninferiority trial, we compared rituximab (375 mg per square meter of body-surface area administered once a week for 4 weeks) followed by placebo with cyclophosphamide administered for 3 to 6 months followed by azathioprine for 12 to 15 months. The primary outcome measure was complete remission of disease by 6 months, with the remission maintained through 18 months. RESULTS: A total of 197 patients were enrolled. As reported previously, 64% of the patients in the rituximab group, as compared with 53% of the patients in the cyclophosphamide-azathioprine group, had a complete remission by 6 months. At 12 and 18 months, 48% and 39%, respectively, of the patients in the rituximab group had maintained the complete remissions, as compared with 39% and 33%, respectively, in the comparison group. Rituximab met the prespecified criteria for noninferiority (P<0.001, with a noninferiority margin of 20%). There was no significant difference between the groups in any efficacy measure, including the duration of complete remission and the frequency or severity of relapses. Among the 101 patients who had relapsing disease at baseline, rituximab was superior to conventional immunosuppression at 6 months (P=0.01) and at 12 months (P=0.009) but not at 18 months (P=0.06), at which time most patients in the rituximab group had reconstituted B cells. There was no significant between-group difference in adverse events. CONCLUSIONS: In patients with severe ANCA-associated vasculitis, a single course of rituximab was as effective as continuous conventional immunosuppressive therapy for the induction and maintenance of remissions over the course of 18 months. (Funded by the National Institute of Allergy and Infectious Diseases and others; RAVE ClinicalTrials.gov number, NCT00104299.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Nomenclature of Systemic Vasculitides
Jennette, J. C., Falk, R. J., Andrassy, K., Bacon, P. A., Churg, J., Gross, W. L., Hagen, E. C., Hoffman, G. S., Hunder, G. G., Kallenberg, C. G. M., et al. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370206 · Cited by 3,845
Self-citationWegener Granulomatosis: An Analysis of 158 Patients
Hoffman, G. S., Kerr, G. S., Leavitt, R. Y., Hallahan, C. W., Lebovics, R. S., Travis, W. D., Rottem, M., & Fauci, A. S. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-6-488 · Cited by 2,857
Self-citationRituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
Stone, J. H., Merkel, P. A., Spiera, R., Seo, P., Langford, C. A., Hoffman, G. S., Kallenberg, C. G. M., St. Clair, E. W., Turkiewicz, A., Tchao, N. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909905 · Cited by 2,762
Self-citationOverview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project
Ware, J. E., & Gandek, B. (1998) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(98)00081-x · Cited by 2,605
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
Jones, R. B., Cohen Tervaert, J. W., Hauser, T., Luqmani, R., Morgan, M. D., Peh, C. A., Savage, C. O., Segelmark, M., Tesar, V., van Paassen, P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909169 · Cited by 1,748
Jayne, D., Rasmussen, N., Andrassy, K., Bacon, P., Tervaert, J. W. C., Dadoniené, J., Ekstrand, A., Gaskin, G., Gregorini, G., de Groot, K., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020286 · Cited by 1,348
de Groot, K., Harper, L., Jayne, D. R. W., Flores Suarez, L. F., Gregorini, G., Gross, W. L., Luqmani, R., Pusey, C. D., Rasmussen, N., Sinico, R. A., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-10-200905190-00004 · Cited by 957
Etanercept plus Standard Therapy for Wegener's Granulomatosis
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa041884 · Cited by 834
De Groot, K., Rasmussen, N., Bacon, P. A., Tervaert, J. W. C., Feighery, C., Gregorini, G., Gross, W. L., Luqmani, R., & Jayne, D. R. W. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21142 · Cited by 801
Azathioprine or Methotrexate Maintenance for ANCA-Associated Vasculitis
Dhawan, R. (2009) · Yearbook of Medicine · doi:10.1016/s0084-3873(09)79350-2 · Cited by 674
Exley, A. R., Bacon, P. A., Luqmani, R. A., Kitas, G. D., Gordon, C., Savage, C. O. S., & Adu, D. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400222 · Cited by 619
Hiemstra, T. F., Walsh, M., Mahr, A., Savage, C. O., de Groot, K., Harper, L., Hauser, T., Neumann, I., Tesar, V., Wissing, K.-M., et al. (2010) · JAMA · doi:10.1001/jama.2010.1658 · Cited by 596
Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study
Booth, A. D., Almond, M. K., Burns, A., Ellis, P., Gaskin, G., Neild, G. H., Plaisance, M., Pusey, C. D., & Jayne, D. R. W. (2003) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(03)00025-8 · Cited by 504
Keogh, K. A., Wylam, M. E., Stone, J. H., & Specks, U. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20718 · Cited by 450
Self-citationLittle, M. A., Nightingale, P., Verburgh, C. A., Hauser, T., De Groot, K., Savage, C., Jayne, D., & Harper, L. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.109389 · Cited by 440
Lionaki, S., Blyth, E. R., Hogan, S. L., Hu, Y., Senior, B. A., Jennette, C. E., Nachman, P. H., Jennette, J. C., & Falk, R. J. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34562 · Cited by 424
Rituximab for Refractory Wegener's Granulomatosis: Report of a Prospective, Open-Label Pilot Trial
Keogh, K. A., Ytterberg, S. R., Fervenza, F. C., Carlson, K. A., Schroeder, D. R., & Specks, U. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200507-1144oc · Cited by 399
Self-citationRisk factors for relapse of antineutrophil cytoplasmic antibody–associated vasculitis
Walsh, M., Flossmann, O., Berden, A., Westman, K., Höglund, P., Stegeman, C., Jayne, D., & European Vasculitis Study Group (2012) · Arthritis & Rheumatism · doi:10.1002/art.33361 · Cited by 363
Self-citationNachman, P. H., Hogan, S. L., Jennette, J. C., & Falk, R. J. (1996) · Journal of the American Society of Nephrology · doi:10.1681/asn.v7133 · Cited by 316
Cartin‐Ceba, R., Golbin, J. M., Keogh, K. A., Peikert, T., Sánchez‐Menéndez, M., Ytterberg, S. R., Fervenza, F. C., & Specks, U. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34584 · Cited by 291
Self-citationANCA Are Detectable in Nearly All Patients with Active Severe Wegener’s Granulomatosis
Finkielman, J. D., Lee, A. S., Hummel, A. M., Viss, M. A., Jacob, G. L., Homburger, H. A., Peikert, T., Hoffman, G. S., Merkel, P. A., Spiera, R., et al. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.08.016 · Cited by 290
Self-citationHolle, J. U., Gross, W. L., Latza, U., Nölle, B., Ambrosch, P., Heller, M., Fertmann, R., & Reinhold‐Keller, E. (2011) · Arthritis & Rheumatism · doi:10.1002/art.27763 · Cited by 270
Smith, R. M., Jones, R. B., Guerry, M., Laurino, S., Catapano, F., Chaudhry, A., Smith, K. G. C., & Jayne, D. R. W. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34583 · Cited by 250
Langford, C. A., Talar‐Williams, C., Barron, K. S., & Sneller, M. C. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199912)42:12<2666::aid-anr24>3.0.co;2-e · Cited by 212
Self-citationDifferential B- and T-cell activation in Wegener’s granulomatosis
Popa, E. R., Stegeman, C. A., Bos, N. A., Kallenberg, C. G. M., & Tervaert, J. W. C. (1999) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(99)70434-3 · Cited by 201
Self-citationSuppression of human B lymphocyte function by cyclophosphamide.
Cupps, T. R., Edgar, L. C., & Fauci, A. S. (1982) · The Journal of Immunology · doi:10.4049/jimmunol.128.6.2453 · Cited by 183
Activation of human B lymphocytes
Fauci, A. S., Whalen, G., & Burch, C. (1980) · Cellular Immunology · doi:10.1016/0008-8749(80)90204-x · Cited by 149
Zhu, L. P., Cupps, T. R., Whalen, G., & Fauci, A. S. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112922 · Cited by 106
Zhong, X., Lim, E. A., Hershman, D. L., Moinpour, C. M., Unger, J. M., & Lee, S. M. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2015.006106 · Cited by 61
Interventions for renal vasculitis in adults
Walters, G. D., Willis, N. S., & Craig, J. C. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003232.pub3 · Cited by 60
Design of the Rituximab in ANCA-Associated Vasculitis (RAVE) Trial
Specks, U., Merkel, P. A., Hoffman, G. S., Langford, C. A., Spiera, R., Seo, P., Kallenberg, C. G. M., Clair, E. W. S., Ding, L., Webber, L., et al. (2011) · The Open Arthritis Journal · doi:10.2174/1876539401104010001 · Cited by 21
Self-citationExpression of host defense scavenger receptors in spondylarthropathy
McBeth (2001) · Pure Amsterdam UMC · doi:10.1002/1529-0131(200104)44:4 · Cited by 1
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Self-citationRituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis
Guillevin, L., Pagnoux, C., Karras, A., Khouatra, C., Aumaître, O., Cohen, P., Maurier, F., Decaux, O., Ninet, J., Gobert, P., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1404231 · Cited by 1,090
RETRACTED: Avacopan for the Treatment of ANCA-Associated Vasculitis
Jayne, D. R. W., Merkel, P. A., Schall, T. J., & Bekker, P. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2023386 · Cited by 1,021
Self-citationRetractedKitching, A. R., Anders, H.-J., Basu, N., Brouwer, E., Gordon, J., Jayne, D. R., Kullman, J., Lyons, P. A., Merkel, P. A., Savage, C. O. S., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0204-y · Cited by 928
Self-citationEULAR recommendations for the management of ANCA-associated vasculitis: 2022 update
Hellmich, B., Sanchez-Alamo, B., Schirmer, J. H., Berti, A., Blockmans, D., Cid, M. C., Holle, J. U., Hollinger, N., Karadag, O., Kronbichler, A., et al. (2024) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-223764 · Cited by 768
Self-citation
Metadata
- Authors
- Specks, U., Merkel, P. A., Seo, P., Spiera, R., Langford, C. A., Hoffman, G. S., Kallenberg, C. G. M., St. Clair, E. W., Fessler, B. J., Ding, L., Viviano, L., Tchao, N. K., Phippard, D. J., Asare, A. L., Lim, N., Ikle, D., Jepson, B., Brunetta, P., Allen, N. B., Fervenza, F. C., Geetha, D., Keogh, K., Kissin, E. Y., Monach, P. A., Peikert, T., Stegeman, C., Ytterberg, S. R., Mueller, M., Sejismundo, L. P., Mieras, K., & Stone, J. H.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-08
- Volume
- 369
- Issue
- 5
- Pages
- 417-427
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2171643265
- Cited by
- 728
- References
- 33
- FWCI
- 57.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.